Literature DB >> 10492375

A new rectal model for dosimetry applications.

G Mardirossian1, M Tagesson, P Blanco, L G Bouchet, M Stabin, H Yoriyaz, S Baza, M Ljungberg, S E Strand, A B Brill.   

Abstract

UNLABELLED: A revised geometric representative model of the lower part of the colon, including the rectum, the urinary bladder and prostate, is proposed for use in the calculation of absorbed dose from injected radiopharmaceuticals. The lower segment of the sigmoid colon as described in the 1987 Oak Ridge National Laboratory mathematical phantoms does not accurately represent the combined urinary bladder/rectal/prostate geometry. In the revised model in this study, the lower part of the abdomen includes an explicitly defined rectum. The shape of sigmoid colon is more anatomically structured, and the diameters of the descending colon are modified to better approximate their true anatomic dimensions. To avoid organ overlap and for more accurate representation of the urinary bladder and the prostate gland (in the male), these organs are shifted from their originally defined positions. The insertion of the rectum and the shifting of the urinary bladder will not overlap with or displace the female phantom's ovaries or the uterus. In the adult male phantom, the prostatic urethra and seminal duct are also included explicitly in the model. The relevant structures are defined for the newborn and 1-, 5-, 10- and 15-y-old (adult female) and adult male phantoms.
METHODS: Values of the specific absorbed fractions and radionuclide S values were calculated with the SIMDOS dosimetry package. Results for 99mTc and other radionuclides are compared with previously reported values.
RESULTS: The new model was used to calculate S values that may be crucial to calculations of the effective dose equivalent. For 131I, the S (prostate<--urinary bladder contents) and S (lower large intestine [LLI] wall<--urinary bladder contents) are 6.7 x 10(-6) and 3.41 x 10(-6) mGy/MBq x s, respectively. Corresponding values given by the MIRDOSE3 computer program are 6.23 x 10(-6) and 1.53 x 10(-6) mGy/MBq x s, respectively. The value of S (rectum wall<--urinary bladder contents) is 4.84 x 10(-5) mGy/MBq x s. For 99mTc, we report S (testes<--prostate) and S (LLI wall<--prostate) of 9.41 x 10(-7) and 1.53 x 10(-7) mGy/MBq x s versus 1.33 x 10(-6) and 7.57 x 10(-6) mGy/MBq x s given by MIRDOSE3, respectively. The value of S (rectum wall<--prostate) for 99mTc is given as 4.05 x 10(-6) mGy/MBq x s in the present model.
CONCLUSION: The new revised rectal model describes an anatomically realistic lower abdomen region, thus giving improved estimates of absorbed dose. Due to shifting the prostate gland, a 30%-45% reduction in the testes dose and the insertion of the rectum leads to 48%-55% increase in the LLI wall dose when the prostate is the source organ.

Entities:  

Mesh:

Year:  1999        PMID: 10492375

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Authors:  Caroline Mitchell; Emily Roemer; Evangelyn Nkwopara; Brian Robbins; Theodore Cory; Tessa Rue; Courtney V Fletcher; Lisa Frenkel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Steven H Jennings; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Melissa Spacek; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

3.  Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Authors:  Kristine B Patterson; Heather A Prince; Eric Kraft; Amanda J Jenkins; Nicholas J Shaheen; James F Rooney; Myron S Cohen; Angela D M Kashuba
Journal:  Sci Transl Med       Date:  2011-12-07       Impact factor: 17.956

4.  Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Julie B Dumond; Melissa B Spacek; Paris E Heidt; Myron S Cohen; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

5.  Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Authors:  Mackenzie L Cottrell; Heather M A Prince; Andrew Allmon; Katie R Mollan; Michael G Hudgens; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Kristine B Patterson; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-15       Impact factor: 3.731

6.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Authors:  Kristine B Patterson; Heather A Prince; Trenton Stevens; Nicholas J Shaheen; Evan S Dellon; Ryan D Madanick; Steven Jennings; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

7.  Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.

Authors:  Yiying Huang; Md Tozammel Hoque; Mohammad-Ali Jenabian; Kishanda Vyboh; Sana-Kay Whyte; Nancy L Sheehan; Pierre Brassard; Maud Bélanger; Nicolas Chomont; Courtney V Fletcher; Jean-Pierre Routy; Reina Bendayan
Journal:  J Antimicrob Chemother       Date:  2016-04-13       Impact factor: 5.790

8.  Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

Authors:  Sulggi A Lee; Sushama Telwatte; Hiroyu Hatano; Angela D M Kashuba; Mackenzie L Cottrell; Rebecca Hoh; Teri J Liegler; Sophie Stephenson; Ma Somsouk; Peter W Hunt; Steven G Deeks; Steven Yukl; Radojka M Savic
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-15       Impact factor: 3.771

9.  Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.

Authors:  Kevin Melody; Chandra N Roy; Christopher Kline; Mackenzie L Cottrell; Dwayne Evans; Kathleen Shutt; Pleuni S Pennings; Brandon F Keele; Moses Bility; Angela D M Kashuba; Zandrea Ambrose
Journal:  J Virol       Date:  2020-03-31       Impact factor: 6.549

10.  Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques.

Authors:  Adam J Kleinman; Cuiling Xu; Mackenzie L Cottrell; Ranjit Sivanandham; Egidio Brocca-Cofano; Tammy Dunsmore; Angela Kashuba; Ivona Pandrea; Cristian Apetrei
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.